A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
Teva Identifier
TV48125-MH-40142 | 2019-001989-15
ClinicalTrials.gov Identifier
NCT04041284
Study Status
Completed
Trial Condition(s)
Migraine | Major Depressive Disorder
Interventions
Drug: Fremanezumab | Drug: Placebo
EudraCT Number
2019-001989-15
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
headache-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 70 Years
Trial Duration
September 13, 2019 - August 31, 2022
Phase
Phase 4

Study Type

Interventional